The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis

Liver International

Volumn 37, Issue 1, 2017, Pages 121-131

  Huang, Yi ^a,b   Adams, Leon A ^a,b   Joseph, John ^c   Bulsara, Max K ^d   Jeffrey, Gary P ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

area under ROC curve; DANA; Hepascore; liver fibrosis

Indexed keywords

ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT TOOL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DISEASE SEVERITY ASSESSMENT; HEPASCORE; HEPATITIS B; HUMAN; LIVER FIBROSIS; META ANALYSIS; MODEL; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PREVALENCE; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ALCOHOL LIVER DISEASE; BLOOD; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; LIVER CIRRHOSIS; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX;

BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HYALURONIC ACID;

BIOMARKERS; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; LIVER DISEASES, ALCOHOLIC; NON-ALCOHOLIC FATTY LIVER DISEASE; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84962708751     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13116     Document Type: Article

References (28)

1. Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26: 21S–8S.
2. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43: S113–20.
3. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867–73.
4. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
5. Poynard T, Halfon P, Castera L, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007; 53: 1615–22.
6. Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making 1993; 13: 313–21.
7. Cacoub P, Carrat F, Bedossa P, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study–ANRS HC02. J Hepatol 2008; 48: 765–73.
8. Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29: 1507–15.
9. Cales P, Halfon P, Batisse D, et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol 2010; 53: 238–44.
10. Lee S, Varano J, Flexman JP, et al. Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virus. Dis Markers 2010; 28: 273–80.
11. Costelloe SJ, Theocharidou E, Tsochatzis E, et al. Hepascore and hyaluronic acid as markers of fibrosis in liver disease of mixed aetiology. Eur J Gastroenterol Hepatol 2015; 27: 313–20.
12. Nguyen-Khac E, Chatelain D, Tramier B, et al. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther 2008; 28: 1188–98.
13. Guechot J, Lasnier E, Sturm N, Paris A, Zarski JP. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta 2010; 411: 86–91.
14. Becker L, Salameh W, Sferruzza A, et al. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol 2009; 7: 696–701.
15. Naveau S, Gaude G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97–105.
16. Adams LA, George J, Bugianesi E, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26: 1536–43.
17. Boursier J, Bacq Y, Halfon P, et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009; 21: 28–38.
18. Bottero J, Lacombe K, Guechot J, et al. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. J Hepatol 2009; 50: 1074–83.
19. Basar O, Yimaz B, Ekiz F, et al. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol 2013; 37: 152–8.
20. Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. World J Gastroenterol 2010; 16: 501–7.
21. Crisan D, Radu C, Lupsor M, et al. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon 2012; 12: 177–84.
22. Cales P, de Ledinghen V, Halfon P, et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352–62.
23. Zarski JP, Sturm N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56: 55–62.
24. Leroy V, Sturm N, Faure P, et al. Prospective evaluation of FibroTest(R), FibroMeter(R), and HepaScore(R) for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol 2014; 61: 28–34.
25. Kalantari H, Hoseini H, Babak A, Yaran M. Validation of hepascore as a predictor of liver fibrosis in patients with chronic hepatitis C infection. Hepat Res Treat 2011; 2011: 972759.
26. Bourliere M, Penaranda G, Ouzan D, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008; 28: 458–67.
27. Raftopoulos SC, George J, Bourliere M, et al. Comparison of noninvasive models of fibrosis in chronic hepatitis B. Hepatol Int 2011; 6: 457–67.
28. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726–36.